

OTA ANNUAL MEETING 2013
ORTHOPAEDIC TRAUMA BOOTCAMP

ORTHOBIOLOGICS FOR ORTHOPAEDICS AND TRAUMATOLOGY

There are clearly no well defined indications for use of a specific type of bone graft substitute or use of inductive factor when dealing with complex fractures, especially when dealing with acute bone and soft tissue defects. The use of all of these materials should be based on contemporary fracture management principles and current levels of evidence for use of these materials

1) Osteoinductive Bone Substitutes

- a) Autologous Bone...considered the GOLD STANDARD...
 - i) There are few reports that actually provide the evidence for the clinical efficacy of autograft.
- b) Allogeneic Bone and Demineralized Bone Matrix
 - i) No reports that carefully evaluate the osteoinductive properties of allograft bone.
 - ii) Animal studies have documented DBM's osteoinductive effects, there is a paucity of clinical information with similar findings.
 - (1) Only one prospective controlled study showing equivalent rates of spinal fusion in the same patients treated with autograft versus a 2:1 ratio composite DBM(gel)/autograft, suggesting potential use DBM as a bone-graft extender. Only anecdotal information is available regarding similar applications in long bone fractures and nonunions.
 - (2) Evidence of differential potencies of DBM preparations based on the manufacturer and manufacturing process.
- c) Bone Morphogenetic Proteins
 - i) Urist, Johnson and colleagues first used the protein in clinical settings. Uncontrolled retrospective series (Level 4 evidence) had encouraging results and stimulated further investigation in this area.
 - ii) Two recombinant BMPs have been developed for clinical use; rhBMP-2 and rhBMP-7 Each has been evaluated in randomized, controlled trials in trauma patients and these studies provide data that qualify as Level 1 evidence.
 - (1) Clinical use for diaphyseal open tibia fractures, long bone nonunion, and spinal fusion.

2) Osteoconductive Bone Graft Substitutes

- a) Allograft
 - i) Level 4 evidence exists for use of cortical allograft in reconstructive and trauma surgery of the humerus and femur. Further research is needed to determine the ideal material for encouraging bone formation with these applications.
 - ii) Calcium ceramic synthetic substitutes

(1) Bone formation by providing an osteoconductive matrix for host osteogenic cells to create bone under the influence of host osteoinductive factors, for use in metaphyseal defects

(2) Recommendations for use

(a) **CaPO₄**: Level B for use as an adjunct to internal or external fixation in fractures of the tibial plateau, intertrochanteric hip fractures and calcaneus fractures. Level A for use in distal radius fractures

(b) **CaSO₄**: Level B for use as a resorbable antibiotic bead in infected nonunions

(i) Level C for use as an adjunct to internal fixation in tibial plateau fractures

(ii) **Allograft**: Level C : no significant published evidence for use in non spinal skeletal fractures

(iii) **Hydroxyapatite** Level A for use in tibial plateaus as an adjunct to internal fixation

3) Materials With Osteogenic Properties

a) Bone marrow aspirate has a high concentration of CTPs. One milliliter of iliac aspirate contains approximately 40 million nucleated cells 1500 of which are CTPs..Clinical use with concentration and implantation for Fx and nonunions.

i) Human data is limited, only case reports treating a limited number of patients demonstrating successful treatment in spinal fusion and nonunion patients (Level 4).

b) Use of Platelet – Rich Plasma and Related Peripheral Blood Concentrates

i) Level 1 evidence in the Basic science literature to strongly support the positive effects and cellular stimulation by these adjuvants as a mechanism for bone repair.

(1) Published prospective comparative studies are currently lacking.

(a) Indications for foot and ankle surgery , diabetics, and smokers. (level 3/4)

SPECIFIC INDICATIONS.....

1) Metaphyseal defects

a) For most metaphyseal defects, it has been shown experimentally that a simple cancellous void will reconstitute on its own and heal completely given a sound biologic environment without the addition of any further grafting material. The danger here is that the subchondral surface will collapse if this defect does not reconstitute fast enough to provide subchondral support with the initiation of wt. bearing

i) Conductive substrates

(1) Ca ceramics. CaSO₄/ CaPO₄

(a) Incorporation characteristics...i.e rates of osteointegration

(b) Ultimate compressive strength mPa

(c) Delivery mechanism. Particulate vs self setting “cements”

(d) Incorporation time vs bone regenerated into defect

(i) Cellular mediated vs chemical degradation of materials

- (ii) Use of marrow concentrates to accelerate incorporation characteristics. “seeding the graft”
 - (e) Multiple studies with good Level I and II evidence support use of both sulfate and phosphate materials for contained metaphyseal defects.
 - (i) Demonstrated superiority over autogenous graft materials.
 - (2) MECHANICAL Factors. Use of conductive substrate materials in metaphyseal defects augmented with use of locking plates for plateau, distal femoral, and pilon fractures
 - (a) MINIMAL evidence currently avail for use of supplementary locking plates in these locations.
- 2) Diaphyseal fractures
- a) Use of adjuvant materials in this location depends on numerous factors
 - i) Evaluation of fx site. Mid shaft tibia fracture is usually a biologically “challenged” region
 - (1) The appropriate migration of cellular components to the site of bone graft or fracture is crucial in continuing the progression of the fracture healing cascade. Consideration of delivering these cells to the region in question.
 - (2) Acute bone loss vs non-union defect
 - (3) Condition of soft tissues and “zone of injury” local environment
 - (a) May require angiography / MRI to determine vascularity/viability of host defect. Most graft failures are as a result of inadequate or poor host nutrition to the local graft region as most fx sites and nonunions are often at the site of thick scar and / or relative avascularity. There is no substitute for preparing the host recipient bed appropriately by resecting the avascular / necrotic tissue and providing healthy tissue for eventual revascularization and thus success of the graft.
 - (b) Flap / soft tissue coverage.....reconstitution of inflammatory phase of Fx healing (neo vascularization)
 - (4) Size of defects
 - (5) Infection status
 - (6) Mechanical stability
 - ii) Acute defect / delayed union / subcritical defect (without total segmental loss) With internal fixation i.e. plate / IM nail
 - (1) Graft options
 - (a) Composite grafts
 - (i) DBM + Autogenous cellular concentrates, +, - platelet gels (as carrier)
 1. Limited success with centrifuged aspirate alone (Connelly, Watson)
 2. Concentration of CFU’s in conjunction with carrier materials (Hernigou) (Jimenez....Astrom technique)
 - iii) Acute critical sized defect / nonunion. (segmental loss <4cm)
 - (1) Graft options
 - (a) BMP-2 implantation at time of wound closure (open tibia fx) (BESTT study results)
 - (b) Segmental defects up to 4 cm (Bucholz, Jones et.al)

- (c) OP-1 (McKee ..Canadian open tibial shaft study)
 - (d) OP-1 for nonunions (equivalent efficacy between autograft and OP-1)
 - (e) Providing scaffolding for mesenchymal cell infiltration. Depending on the temporal relationship of the delivery of the inductive factor to the cell population in question, will determine the specific effect that each protein has on the fracture healing cascade. It is important that these stem cells have the appropriate conductive surface to migrate on to initiate the further production of their specific induced function.
 - (f) Providing Colony forming units (CFU's) (Hernigou)
- iv) Large segmental defects
- (1) Staged reconstruction
 - (a) Antibiotic spacer / beads / rods
 - (i) Carrier for inductive materials
 - (ii) Carrier for antibiotics
 - 1. PMA
 - 2. CaSO⁴
 - (b) Development of vascularized pseudo-membranes.. Masquelet technique)
 - (i) Grafting directly into vascularized pseudo membrane
Using RIA derived bone graft.
 - (ii) Membrane directed bone regeneration
 - (2) Bone transport
 - (a) Segmental bone loss remains problematic and usually requires massive quantities of graft material, whether it be a composite graft utilizing transplant of autogenous cellular material in combination with a competent osteoconductive substrate as well as inductive proteins are necessary to bridge large structural defects. Problems here include the lack of rapid remodeling and as such these defects are prone to fatigue failure and stress fracture. Large segmental defects often require bone transport versus free tissue transfer such as vascularized iliac crest or free fibula or combinations of both.
 - (b) Ultrasound directed rapid transport of over nail with autodistractors
 - (c) Augmentation of rapid regenerate with BMP's
 - (3) Free tissue transfer
 - (a) Combination methodologies with bone transport and inductive factor augmentation
 - (4) Ti cage / graft / IM nail.... defect replacement (Lindsey)
- 3) Adjuvant therapies
- a) Ultrasound...LIPUS (Low Intensity Pulsed Ultrasound) for treatment of fresh fractures
 - i) Heckman. Et al....Fresh tibial shaft fxs. Effective: 24%(clinical) and 38% (clinical and radiographic) acceleration
 - ii) Leung....Tibial shaft fx. With comminution IM nail / ex fix. Effective: 42% Acceleration.
 - b) Ultrasound ...for delayed and nonunions

- i) Prospective cohort studies revealed that the overall success rate of LIPUS for nonunions is 55% to 100%
- c) Ultrasound adjuvant to distraction osteogenesis (Gold et al.)

Many basic science and some clinical trials have shown that LIPUS could be a useful method for enhancement or acceleration of healing in some kinds of fresh fractures and nonunions. However, the role of LIPUS for fracture healing is still unknown because of the heterogeneity of results in clinical trials for fresh fractures and the lack of controlled trials for delayed unions and nonunions. There is still a need for more RCTs with large numbers of participating patients from multiple centers.

References

1. Tiedeman JJ, Garvin KL, Kile TA, et al. The role of a composite, demineralized bone matrix and bone marrow in the treatment of osseous defects. *Orthopaedics* 1995;18:12:1153-1158.
2. Johnson EE, Urist MR, Finerman GAM. Bone morphogenetic protein augmentation grafting of resistant femoral non-unions. A preliminary report. *Clin. Orthop.*, 230:257-265, 1988.
3. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein 1 (bone morphogenetic protein 7) in the treatment of tibial nonunions. *J Bone Joint Surg Am* 2001;83:S151-158.
4. Govender S, Csimma C, Genant HK et al. Recombinant human bone morphogenetic protein 2 for treatment of open tibial fractures. A prospective, controlled, randomized study of four hundred and fifty patients. *J Bone Joint Surg Am* 2002,84:12:2123-2134.
5. McKee MD, Schemitsch EH, Waddell JP, Kreder HJ, Stephen DJG, Leighton RK, Buckley RE, Powell JN, Wild LM, Blachut PA, O'Brien PJ, Pirani S, McCormack RG. The effect of rhBMP-7 on the healing of open tibial shaft fractures: Results of a multicenter, prospective randomized clinical trial. Proceedings of the 18th Annual Meeting of the Orthopaedic Trauma Association, Oct 12, 2002, p157-158.
6. Bucholz RW, Carlton A and Holmes R. Interporous hydroxyapatite as a bone graft substitute in tibial plateau fractures. *Clin Orthop*, (240): 53-62, 1989.
7. Larsson S and Bauer TW. Use of injectable calcium phosphate cement for fracture fixation: a review. *Clin Orthop*, (395): 23-32, 2002.
8. Kopylov P, Runnqvist K, Jonsson K and Aspenberg P. Norian SRS versus external fixation in redisplaced distal radial fractures. A randomized study in 40 patients. *Acta Orthop Scand*, 70(1): 1-5, 1999.
9. Zimmerman R, Gabl M, Lutz M, Angermann P, Gschwentner M and Pechlaner S. Injectable calcium phosphate bone cement Norian SRS for the treatment of intra-articular compression fractures of the distal radius in osteoporotic women. *Arch Orthop Trauma Surg*, 123(1): 22-7, 2003.

10. Cassidy C, et al. Norian SRS cement compared with conventional fixation in distal radial fractures. A randomized study. *J Bone Joint Surg Am*, 84-A(11): 2127-37, 2003.
11. Lobenhoffer P, Gerich T, Witte F and Tscherne H. Use of an injectable calcium phosphate bone cement in the treatment of tibial plateau fractures: a prospective study of twenty-six cases with twenty-month mean follow-up. *J Orthop Trauma*, 16(3): 143-9, 2002.
12. Watson JT. The Use of an Injectable Bone Graft Substitute in Tibial Metaphyseal Fractures. *Orthopedics* 27(1): 103-105, 2004.
13. Horstmann WG, Verheyen CC and Leemans R. An injectable calcium phosphate cement as a bone-graft substitute in the treatment of displaced lateral tibial plateau fractures. *Injury*, 34(2): 141-4, 2003.
14. Schildhauer TA, Bauer TW, Josten C and Muhr G. Open reduction and augmentation of internal fixation with an injectable skeletal cement for the treatment of complex calcaneal fractures. *J Orthop Trauma*, 14(5): 309-17, 2000.
15. Muschler GF, Midura MJ. Connective Tissue Progenitors: Practical Concepts for Clinical Applications. *Clin Orthop* 2002; 395:66-80.
16. Muschler, GF, Midura RJ, Nakamoto C. Practical modeling concepts for connective tissue stem cell and progenitor compartment kinetics. *J Biomed Biotechnol*. 2003;3(2003)1-20.
17. Hernigou P et al; Percutaneous Autologous Bone-Marrow Grafting for Nonunions. *J. Bone and Joint Surg.*, 87-A No. 7 July 2005
18. Hernigou P et al; Treatment of Osteonecrosis with Autologous Bone Marrow Grafting. *Clin Orthopaedics and Rel Res.*, 405: 14 – 23, 2002
19. Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. *J Bone Joint Surg Am*. 2004 Jul; 86-A (7):1541-1558.
20. Muschler, GF, Boehm, C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. *J Bone Joint Surg Am* 1997Nov (11):1699-1709
21. Connolly JF, Guse R, Tiedeman J, Dehne R. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. *Clin Orthop* 1991; 266:259-269.
22. Connolly J, Guse R, Lippiello L, Dehne R. Development of an osteogenic bone-marrow preparation. *J. Bone and Joint Surg*. 1998; 5:684-690.
23. Tiedeman JJ, Connolly JF, Strates BS, Lippiello L. Treatment of nonunion by percutaneous injection of bone marrow and demineralized bone matrix. An experimental study in dogs. *Clin Orthop*.1991 Jul ;(268):294-302.
24. Brude Slater M, et al. Involvement of Platelets in Stimulating Osteogenic Activity *J Ortho Research* 13:655-663, 1995.
25. Marx RE, Carlson ER, Eichstaaedt RM, et. al, Platelet Rich Plasma; Growth Factor Enhancement for Bone Grafts. June 1998, *J Ortho Research* 85(6) 13:655-663, 1995.
26. Cierny G, Zorn KL. Segmental tibial defects, comparing conventional and Ilizarov methodologies. *Clin. Orthop*. 301: 118-133, 1994.

27. Green SA, Jackson JM, Wall DM, Marinow H, Ishkanian J. Management of segmental defects by the Ilizarov intercalary bone transport method. *Clin Orthop*: 280:136-142, 1992.
28. Gold SM, Wasserman R. Preliminary results of tibial bone transports with pulsed low intensity ultrasound (Exogen). *J Orthop Trauma*. 19(1):10-6, 2005.
29. Lowenberg DW, Feibel RJ, Louie KW, Eshima I. Combined muscle flap and Ilizarov reconstruction for bone and soft tissue defects. *Clin Orthop*. 332:37-51, 1996.
30. Mahaluxmivala J, Nadarajah R, Allen PW, Hill RA.: Ilizarov external fixator: acute shortening and lengthening versus bone transport in the management of tibial non-unions. *Injury*. 36(5):662-668, 2005.
31. Matsuyama J, Ohnishi I, Kageyama T, Oshida H, Suwabe T, Nakamura K. Osteogenesis and angiogenesis in regenerating bone during transverse distraction: quantitative evaluation using a canine model. *Clin Orthop*. 433: 243-250, 2005.
32. Mekhail AO, Abraham E, Gruber B, Gonzalez M. Bone transport in the management of posttraumatic bone defects in the lower extremity. *J Trauma*. 56(2):368-378, 2004.
33. Oedekoven G, Jansen D, Raschke M, Claudi BF: The monorail system--bone segment transport over unreamed interlocking nails. *Chirurg*. 67(11):1069-1079, 1996.
34. Song HR, Kale A, Park HB, Koo KH, Chae DJ, Oh CW, Chung DW: Comparison of internal bone transport and vascularized fibula femoral bone defects. *J Orthop Trauma*. 17(3):203-211, 2003.
35. Watson JT. Treatment of Tibial Fractures with Bone Loss. *Techniques in Orthop*. 11(2): 132-143, 1996.
36. Watson JT, Anders, M, Moed BR: Management Strategies for Bone Loss in Tibial Shaft Fractures. *Clin Orthop*. 315:138-152, 1995.
37. Rozbruch RS, Weitzman AM, Watson JT, Freudigman P, et.al. Simultaneous Treatment of Tibial Bone and Soft –tissue Defects with the Ilizarov Method. *J Ortho Trauma* 20(3):197-205, 2006.
38. Watson JT, Distraction Osteogenesis. *Journal of AAOS Oct*; 14(10) 168-74. 2006.
39. DeLong, W, Einhorn, T, Koval, K, Watson JT, et.al. Bone Grafts and Bone Graft Substitutes in Orthopaedic Trauma Surgery. A critical analysis. *J Bone Joint Surg Am*. 2007 Mar;89(3):649-58. Review.
40. Quigley K, Watson JT, Mudd C, Iliac Crest Aspiration and Injection in the Treatment of Delayed and Nonunion. Paper Presentation. Abstracts of the 22nd Annual Meeting OTA. Phoenix ,AZ. Oct 3-7, 2006.
41. Hernigou P et al; Percutaneous Autologous Bone-Marrow Grafting for Nonunions. *J. Bone and Joint Surg.*, 87-A No. 7 July 2005
42. Hernigou P et al; Treatment of Osteonecrosis with Autologous Bone Marrow Grafting. *Clin Orthopaedics and Rel Res.*, 405: 14 – 23, 2002
43. Heckman JD, Ryaby JP, McCable J, et al. Acceleration of tibial fracture healing by non-invasive, low-intensity pulsed ultrasound. *J Bone Joint Surg Am*. 1994;76:26–34.
44. Leung KS, Lee WS, Tsui HF, et al. Complex tibial fracture outcomes

following treatment with low-intensity pulsed ultrasound. *Ultrasound Med Biol.* 2004;22:486–490.

45. Gold SM, Wasserman R. Preliminary results of tibial bone transports with pulsed low intensity ultrasound (Exogen). *J Orthop Trauma.* 2005; 19:10–16.